Altimmune (ALT) Other financing activities (2010 - 2026)

Altimmune (ALT) has 15 years of Other financing activities data on file, last reported at $177000.0 in Q1 2026.

• On a quarterly basis, Other financing activities rose 4.12% year-over-year to $177000.0 in Q1 2026; TTM through Mar 2026 was $298000.0, a 83.95% increase from a year earlier, with the FY2025 full-year figure at $291000.0, up 80.75% from the prior year.
• Other financing activities for Q1 2026 stood at $177000.0, down from $283000.0 in the prior quarter.
• Over the last five years, Other financing activities for ALT reached as high as $755000.0 in Q3 2022 and fell as low as -$162000.0 in Q2 2025.
• Historically, Other financing activities has averaged $153818.2 across 5 years, with a median of $113000.0 in 2022.
• Across the five-year window, Other financing activities sank 46.02% in 2023 and surged 3637.5% in 2025, its largest moves.
• Year by year, Other financing activities stood at $82000.0 in 2022, then sank by 36.59% to $52000.0 in 2023, then tumbled by 115.38% to -$8000.0 in 2024, then jumped by 3637.5% to $283000.0 in 2025, then slumped by 37.46% to $177000.0 in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $177000.0 in Q1 2026, $283000.0 in Q3 2025, and -$162000.0 in Q2 2025.